United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals limited - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - irbesartan 75 mg - irbesartan tablets usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with dif

Canada - English - Health Canada

angita pharma inc. - irbesartan; hydrochlorothiazide - tablet - 150mg; 12.5mg - irbesartan 150mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

angita pharma inc. - irbesartan; hydrochlorothiazide - tablet - 300mg; 12.5mg - irbesartan 300mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

angita pharma inc. - irbesartan; hydrochlorothiazide - tablet - 300mg; 25mg - irbesartan 300mg; hydrochlorothiazide 25mg - angiotensin ii receptor antagonists

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.this fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone (see section 5.1).

European Union - English - EMA (European Medicines Agency)

sanofi-aventis groupe  - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. this fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

European Union - English - EMA (European Medicines Agency)

teva b.v.  - irbesartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension. this fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - irbesartan -